TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7604143

Group type: EXPERIMENTAL
Intervention: Progesterone (mean daily dose of 1983 mg for 3 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 43
Study: 2118110

Group type: EXPERIMENTAL
Intervention: CO2-clamp experiment (inspiratory CO2 manipulated to hold end-tidal P(CO2) near 6.5 kPa (49 mm Hg))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Reference experiment (end-tidal P(O2) maintained at 17.3 kPa)
Number of subjects: 9
Study: 155322

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) in combination with nitrosourea (streptozotocin)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) in combination with lactone (spironolactone)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) in combination with both nitrosourea and lactone
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) in combination with nitrosourea (methyl CCNU)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) in combination with lactone (testolactone)
Number of subjects: 355
Study: 31840424

Group type: EXPERIMENTAL
Intervention: Advanced Routine (AR: Cleanser/Toner/Eye cream/Serum/Day & Night cream)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Simple Routine (SR: Cleanser & Day cream)
Number of subjects: 49
Study: 30721143

Group type: EXPERIMENTAL
Intervention: Fenugreek transdermal patch 10% (FDP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diclofenac dermal patch 1% (DP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 28315017

Group type: EXPERIMENTAL
Intervention: Ear acupuncture in addition to local anesthesia with articain
Number of subjects: 100

Group type: COMPARATOR
Intervention: Local anesthesia with articain only (Control)
Number of subjects: 100
Study: 25595452

Group type: EXPERIMENTAL
Intervention: Distraction Osteogenesis (DO)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Bilateral Sagittal Split Osteotomy (BSSO)
Number of subjects: 63
Study: 24472527

Group type: EXPERIMENTAL
Intervention: Sugarsquare web-based patient portal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual pediatric diabetes care (Control)
Number of subjects: 0
Study: 22418740

Group type: EXPERIMENTAL
Intervention: Psychophysical technique to bias stimuli towards the intact ventral visual pathway
Number of subjects: 0
Study: 18398423

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption the night before glycaemic index testing
Number of subjects: 0
Study: 17254029

Group type: EXPERIMENTAL
Intervention: Local narrowband UVB phototherapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Local paint-PUVA using 0.1% 8-methoxypsoralen gel
Number of subjects: 15
Study: 15207885

Group type: EXPERIMENTAL
Intervention: Continuous oral 17beta-oestradiol (1 mg per day) combined with norgestimate (90 microg per day) for 3 consecutive days out of every 6-day treatment period (E2/iNGM)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 12384637

Group type: EXPERIMENTAL
Intervention: Rotational atherectomy (rotablation)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Re-dilatation
Number of subjects: 300
Study: 9803426

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.25, 0.50, 0.75 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study: 7652500

Group type: EXPERIMENTAL
Intervention: Meropenem (1 g)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Cefotaxime (2 g) plus Metronidazole (500 mg)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Imipenem/Cilastatin (1 g)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Meropenem (500 mg)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Imipenem/Cilastatin (500 mg)
Number of subjects: 641
Study: 2676750

Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin (5 cycles)
Number of subjects: 72
Study: 7249528

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (H1-receptor antagonist)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cimetidine (H2-receptor antagonist)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (sodium chloride solution)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cimetidine and Chlorpheniramine together
Number of subjects: 36
Study: 30987603

Group type: EXPERIMENTAL
Intervention: 0.5 h LSFSL
Number of subjects: 400

Group type: COMPARATOR
Intervention: 4 h LSFSL
Number of subjects: 400
Study: 28456509

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g intravenous)
Number of subjects: 20060

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g intravenous) within 3 hours of giving birth
Number of subjects: 20060

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20060
Study: 25573527

Group type: EXPERIMENTAL
Intervention: Thalidomide (100-300 mg daily) plus dexamethasone (12 mg/m2 on days 1-4 of a 28-day cycle)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus dexamethasone (12 mg/m2 on days 1-4 of a 28-day cycle)
Number of subjects: 0
Study: 23564919

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 755

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 755
Study: 21294770

Group type: EXPERIMENTAL
Intervention: Sensor-augmented insulin pump therapy (n = 44)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Multiple daily injections (n = 39)
Number of subjects: 83
Study: 19817242

Group type: EXPERIMENTAL
Intervention: E-glove
Number of subjects: 9

Group type: COMPARATOR
Intervention: G-glove
Number of subjects: 9

Group type: COMPARATOR
Intervention: Bare hand
Number of subjects: 9
Study: 18841284

Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment (75 mg/d)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Aspirin only
Number of subjects: 133
Study: 15184286

Group type: EXPERIMENTAL
Intervention: Pulmonary vein (PV) isolation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Linear ablation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Comparison of AFCL increase
Number of subjects: 70
Study: 11604183

Group type: EXPERIMENTAL
Intervention: Amnioinfusion via two-way catheter
Number of subjects: 206

Group type: COMPARATOR
Intervention: No amnioinfusion (control group)
Number of subjects: 206
Study: 9247406

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 5
Study: 8513522

Group type: EXPERIMENTAL
Intervention: 5 ml bupivacaine, 0.125% in normal saline followed by the same amount of bupivacaine dissolved in 50% glycerin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 5 ml bupivacaine, 0.125% in 50% glycerin followed by the same amount of bupivacaine in normal saline
Number of subjects: 27

Group type: COMPARATOR
Intervention: Plain 50% glycerin
Number of subjects: 27
Study: 3104371

Group type: EXPERIMENTAL
Intervention: Therapist-assisted relaxation treatment
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Self-help relaxation treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Self-monitoring condition
Number of subjects: 46
Study: 11465228

Group type: EXPERIMENTAL
Intervention: INR self-management at home
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monitoring by family practitioners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: INR self-management
Number of subjects: 0
Study: 31430297

Group type: EXPERIMENTAL
Intervention: ASO3B adjuvanted split virion vaccine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Whole virion non‐adjuvanted vaccine
Number of subjects: 22
Study: 29946652

Group type: EXPERIMENTAL
Intervention: Combined muscle functions intensifier and straight wire appliance (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Straight wire appliance only (group B)
Number of subjects: 40
Study: 27148633

Group type: EXPERIMENTAL
Intervention: intervention plus booster
Number of subjects: 213

Group type: COMPARATOR
Intervention: intervention only
Number of subjects: 213
Study: 25300863

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 4410

Group type: EXPERIMENTAL
Intervention: Emtricitabine plus tenofovir disoproxil fumarate
Number of subjects: 4410

Group type: COMPARATOR
Intervention: Placebo (discontinued)
Number of subjects: 4410

Group type: EXPERIMENTAL
Intervention: Detection of tenofovir in plasma samples (tenofovir disoproxil fumarate group)
Number of subjects: 4410

Group type: EXPERIMENTAL
Intervention: Detection of tenofovir in plasma samples (emtricitabine plus tenofovir disoproxil fumarate group)
Number of subjects: 4410
Study: 23018281

Group type: EXPERIMENTAL
Intervention: Amisulpride 800 mg/day (AMI-800 group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Amisulpride 400 mg/day (AMI-400 group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups (AMI-400 and AMI-800)
Number of subjects: 68
Study: 23023308

Group type: EXPERIMENTAL
Intervention: Esmolol 1.5 mg/kg iv 90 seconds before intubation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Esmolol 1.5 mg/kg iv 3 minutes before intubation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Esmolol 1.5 mg/kg iv 6 minutes before intubation
Number of subjects: 60
Study: 17646693

Group type: EXPERIMENTAL
Intervention: Upper WBC quartiles (7.3-8.8; >=8.9 x 10(9)/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upper WBC quartiles (vs. lowest quartile)
Number of subjects: 0
Study: 15710939

Group type: EXPERIMENTAL
Intervention: HIV-1 vaccine trial participants
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Participants believing they received the vaccine
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Participants believing vaccine efficacy was greater than 50%
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Participants believing they received the vaccine and that vaccine efficacy was greater than 50%
Number of subjects: 291
Study: 12189543

Group type: EXPERIMENTAL
Intervention: Epirubicin 20 mg m(‐2) for 3 weeks followed by 1 week of rest (1 cycle) and gemcitabine 1000 mg m(‐2) after Epirubicin on the same day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Epirubicin and gemcitabine combination therapy
Number of subjects: 44
Study: 10071291

Group type: EXPERIMENTAL
Intervention: Chemotherapy (tamoxifen, cisplatin, and dacarbazine)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Chemoimmunotherapy (chemotherapy followed by interferon alfa-2b and interleukin-2)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 102
Study: 7585854

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) Aqueous nasal spray (220 micrograms once daily)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 2188493

Group type: EXPERIMENTAL
Intervention: Controlled-release isosorbide-5-mononitrate 60 mg once daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional isosorbide dinitrate 20 mg 3 times daily
Number of subjects: 33
Study: 7391236

Group type: EXPERIMENTAL
Intervention: Autobiographical Recollections
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Structural Set of Mood Statements
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (depression-related induction)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (elation-related induction)
Number of subjects: 206
Study: 31187937

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with 10% 5-aminolevulinic acid (ALA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Photodynamic therapy with 5% 5-aminolevulinic acid (ALA)
Number of subjects: 23
Study: 31575701

Group type: EXPERIMENTAL
Intervention: CROMRIS tool (MRI scoring tool)
Number of subjects: 45
Study: 28836954

Group type: EXPERIMENTAL
Intervention: Intervention Group 1 (IG1; n = 169) - therapists provided with feedback about patients' self-evaluation in a computerized feedback portal.
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Intervention Group 2 (IG2; n = 169) - therapists provided with feedback and clinical support tools, along with personalized treatment recommendations.
Number of subjects: 423

Group type: COMPARATOR
Intervention: Control Group (CG; n = 85) - monitored for psychological impairment without feedback provided to therapists.
Number of subjects: 423
Study: 26152008

Group type: EXPERIMENTAL
Intervention: Novasure impedance control system
Number of subjects: 66

Group type: COMPARATOR
Intervention: Microwave endometrial ablation (MEA)
Number of subjects: 66
Study: 24144472

Group type: EXPERIMENTAL
Intervention: F4/AS01 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22647321

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation treatment (MRT)
Number of subjects: 120
Study: 20214338

Group type: EXPERIMENTAL
Intervention: Qingyi Decoction (QYD)
Number of subjects: 110
Study: 17854421

Group type: EXPERIMENTAL
Intervention: Parent-based group education programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 15229011

Group type: EXPERIMENTAL
Intervention: Vulvodolorimeter testing at vulvar locations
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Discrete ascending pressure stimuli to the thumb
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Random staircase pressure stimuli to the thumb
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dolorimeter testing at thumb, deltoid, and shin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cotton-tipped swab testing
Number of subjects: 17
Study: 11421876

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate with amoxicillin and clarithromycin (RAC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate with metronidazole and tetracycline (BMT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate with metronidazole and tetracycline (RMT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Omeprazole with amoxicillin and clarithromycin (OAC)
Number of subjects: 200
Study: 9458489

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 7948453

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication after 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo after 1 week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Higher blood levels of antipsychotic medication
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Higher levels of cerebrospinal fluid (CSF) MHPG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Number of subjects: 30
Study: 3129114

Group type: EXPERIMENTAL
Intervention: Continuous treatment with cimetidine 400 mg at bedtime
Number of subjects: 267

Group type: COMPARATOR
Intervention: Intermittent 'healing' doses of cimetidine for 4 to 8 weeks
Number of subjects: 267
Study: 30805618

Group type: EXPERIMENTAL
Intervention: Graphic text messages
Number of subjects: 71

Group type: COMPARATOR
Intervention: Text-only messages
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Quitline information
Number of subjects: 71

Group type: COMPARATOR
Intervention: Quitting tips
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 71
Study: 28550902

Group type: EXPERIMENTAL
Intervention: Axillary plexus block with mepivacaine 1% and ropivacaine 0.75% in a 3:1 ratio
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Axillary plexus block
Number of subjects: 20
Study: 25641245

Group type: EXPERIMENTAL
Intervention: Patients with juvenile idiopathic arthritis (JIA)
Number of subjects: 54911

Group type: COMPARATOR
Intervention: Patients without juvenile idiopathic arthritis (JIA)
Number of subjects: 54911
Study: 24326120

Group type: EXPERIMENTAL
Intervention: STb lingual appliance
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Roth labial appliance
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 20
Study: 21767934

Group type: EXPERIMENTAL
Intervention: Long acting injection risperidone (RLAI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral risperidone (RisO)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 24
Study: 19336535

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: LMA CTrach
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: AWS (Pentax AWS)
Number of subjects: 90
Study: 16730497

Group type: EXPERIMENTAL
Intervention: Face-to-face medical training/education of providers
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Provision of an IUD checklist
Number of subjects: 40
Study: 15268830

Group type: EXPERIMENTAL
Intervention: Burst group (vacuum 250-300 mm Hg, power 60%)
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Pulse group (vacuum 160 mm Hg, power 60%)
Number of subjects: 819

Group type: COMPARATOR
Intervention: Continue group (vacuum 160 mm Hg, power 60%)
Number of subjects: 819
Study: 11101480

Group type: EXPERIMENTAL
Intervention: Zinc supplementation with oral rehydration therapy
Number of subjects: 0
Study: 8840213

Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy (DCA) for immediate residual stenosis > or = 75% after thrombolysis
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy (DCA) for suboptimal results after immediate percutaneous transluminal coronary angioplasty (rescue DCA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Subintimal resection
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intimal resection
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison of subintimal vs intimal resection
Number of subjects: 44
Study: 1612357

Group type: EXPERIMENTAL
Intervention: Sodium butyrate (100 mmol/L)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6734925

Group type: EXPERIMENTAL
Intervention: Difflam Oral Rinse (benzydamine hydrochloride 0.15% w/v)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soluble aspirin (acetyl salicylic acid)
Number of subjects: 0
Study: 30953536

Group type: EXPERIMENTAL
Intervention: Short-term mentalization-based therapy (20 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term mentalization-based therapy (14 months)
Number of subjects: 0
Study: 28459938

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Residual Cancer Burden (RCB) class
Number of subjects: 800
Study: 26461858

Group type: EXPERIMENTAL
Intervention: Intervention (10 weekly educational sessions led by promotoras)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 254
Study: 23788755

Group type: EXPERIMENTAL
Intervention: Bevacizumab + Erlotinib (arm A)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Bevacizumab alone (arm B)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) from start of induction chemotherapy
Number of subjects: 249
Study: 21399902

Group type: EXPERIMENTAL
Intervention: Clonidine 0.1 mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 19565569

Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Insulin glargine (IGla)
Number of subjects: 385
Study: 17156144

Group type: EXPERIMENTAL
Intervention: New sampling method (stricture dilation and a grasping basket)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Biliary brushing (control)
Number of subjects: 60
Study: 14709455

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 60
Study: 11815493

Group type: EXPERIMENTAL
Intervention: Culturally competent diabetes self-management education intervention over 12 months, consisting of 52 contact hours, including 3 months of weekly sessions and 6 months of biweekly support group sessions.
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (not specified in detail in the abstract).
Number of subjects: 256
Study: 10414041

Group type: EXPERIMENTAL
Intervention: Quinine (750-850 mg for 24 hours over 4.1 +/- 1.7 days)
Number of subjects: 91
Study: 8748629

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2027071

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg to start and 100 mg per day for 3 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 27
Study: 7250175

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN) 30 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sustained released ISDN 20 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN) 20-30 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN) 5 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN) 10 to 50 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN)
Number of subjects: 13
Study: 6707811

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation with cold air (IHCA)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Exercise test
Number of subjects: 23

Group type: COMPARATOR
Intervention: IHCA
Number of subjects: 23
Study: 29053202

Group type: EXPERIMENTAL
Intervention: ITCA 650 (20 μg/day)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: ITCA 650 (40 μg/day)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Ex-BID (10 μg BID)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: ITCA 650 (after switching from Ex-BID)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: ITCA 650 (after 3-fold dose escalation)
Number of subjects: 155